

**Patient Information** Fax completed form, insurance information and clinical documentation to 515.559.2495.

**Patient Name:** \_\_\_\_\_ **DOB:** \_\_\_\_\_ **Phone:** \_\_\_\_\_

**Patient Status:**      New to Therapy      Continuing Therapy      **Next Treatment Date:** \_\_\_\_\_

**Medical Information**

**Diagnosis:**    Plaque psoriasis    (ICD-10 code: L40.0)  
Other: \_\_\_\_\_ **ICD-10 Code:** \_\_\_\_\_

**Patient Weight:** \_\_\_\_\_ lbs. (required) **Allergies:** \_\_\_\_\_

**Therapy Order**

**Initial dosing (New Start):**  
100 mg subcutaneously at weeks 0 and 4, then every 12 weeks thereafter x1 year

**OR**

**Maintenance dosing:**  
100 mg subcutaneously every 12 weeks x1 year

**Lab Orders:** \_\_\_\_\_ **Lab Frequency:** \_\_\_\_\_

Yearly TB QFT screening (optional)

Required labs to be drawn by:    Infusion Center    Referring Provider

**Provider Information**

By signing this form and utilizing our services, you are authorizing *Hy-Vee Health* and its employees to serve as your prior authorization and specialty pharmacy designated agent in dealing with medical and prescription insurance companies, and to select the preferred site of care for the patient.

**Provider Name:** \_\_\_\_\_ **Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**Provider NPI:** \_\_\_\_\_ **Phone:** \_\_\_\_\_ **Fax:** \_\_\_\_\_ **Contact Person:** \_\_\_\_\_

Opt out of Hy-Vee Health selecting site of care (if checked, please list site of care): \_\_\_\_\_

**Service Areas**

Des Moines, IA      West Des Moines, IA      Chicago, IL      Omaha, NE      Buffalo, NY      Dallas, TX

Phoenix, AZ      Other \_\_\_\_\_

HY-VEEHEALTHINFUSION.COM

**IMPORTANT NOTICE:** This fax is intended to be delivered only to the named addressee and contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.

## Patient Information

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_

## Required Documentation for Referral Processing & Insurance Approval

Include signed and completed order (MD/prescriber to complete page 1)

Include patient demographic information and insurance information

Include patient's medication list

Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits or contraindications to conventional therapy

Has the patient had a documented contraindication/intolerance or failed trial of a corticosteroids, vitamin D analogs, calcineurin inhibitors or Anthralin?    Yes    No

If yes, which drug(s)? \_\_\_\_\_

Percent of body surface (BSA) involved: \_\_\_\_\_ %

Has the patient tried and failed methotrexate?    Yes    No

Does the patient have a contraindication/intolerance or failed trial to any biologics (i.e., Humira, Skyrizi, Tremfya, Cosentyx, Stelara, Cimzia)?    Yes    No

If yes, which drug(s)? \_\_\_\_\_

Include labs and/or test results to support diagnosis

Is the patient or caregiver not competent or physically unable to administer Ilumya for self-administration?    Yes    No

Other Medical Necessity: \_\_\_\_\_

## Required Prescreening

**TB screening test completed within 12 months – attach results**

**Positive    Negative**

\*If TB or Hepatitis B results are positive, please provide documentation of treatment or medical clearance, and a negative CXR (TB+)

Hy-Vee Health will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

HY-VEEHEALTHINFUSION.COM

**IMPORTANT NOTICE:** This fax is intended to be delivered only to the named addressee and contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.